GW-TT5

GW-TT5 is an investigational AAV-based gene therapy being developed by Gateway Biotechnology for the treatment of severe debilitating and chronic tinnitus. The therapy utilizes a chemogenetic approach involving Designer Receptors Exclusively Activated by Designer Drugs (DREADD). It employs an Adeno-Associated Virus (AAV) vector to deliver genetic instructions for these designer receptors specifically to inhibitory neurons within the caudate nucleus (CN) of the auditory pathway. Once expressed, these receptors can be selectively activated by a specific designer drug to modulate neuronal firing and suppress the perception of tinnitus. GW-TT5 is currently in preclinical development, with animal studies showing promise and an Investigational New Drug (IND) submission anticipated by the end of 2026.